240 related articles for article (PubMed ID: 9452278)
1. The use of epithelial membrane antigen and silver-stained nucleolar organizer regions testing in the differential diagnosis of mesothelioma from benign reactive mesothelioses.
Wolanski KD; Whitaker D; Shilkin KB; Henderson DW
Cancer; 1998 Feb; 82(3):583-90. PubMed ID: 9452278
[TBL] [Abstract][Full Text] [Related]
2. Comparison of silver-staining nucleolar organizer region (AgNOR) counts and proliferating cell nuclear antigen (PCNA) expression in reactive mesothelial hyperplasia and malignant mesothelioma.
Bethwaite PB; Delahunt B; Holloway LJ; Thornton A
Pathology; 1995 Jan; 27(1):1-4. PubMed ID: 7603742
[TBL] [Abstract][Full Text] [Related]
3. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
[TBL] [Abstract][Full Text] [Related]
4. Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports.
King J; Thatcher N; Pickering C; Hasleton P
Histopathology; 2006 Dec; 49(6):561-8. PubMed ID: 17163840
[TBL] [Abstract][Full Text] [Related]
5. The use of epithelial membrane antigen and silver-stained nucleolar organizer regions testing in the differential diagnosis of mesothelioma from benign reactive mesothelioses.
Metze K; Trevisan MA
Cancer; 1999 Jan; 85(1):250. PubMed ID: 9922003
[No Abstract] [Full Text] [Related]
6. Evaluation of AgNOR count in distinguishing benign from malignant mesothelial cells in pleural fluids.
Colecchia M; Leopardi O
Pathol Res Pract; 1992 Jun; 188(4-5):541-4. PubMed ID: 1409085
[TBL] [Abstract][Full Text] [Related]
7. The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis.
Cury PM; Butcher DN; Corrin B; Nicholson AG
J Pathol; 1999 Oct; 189(2):251-7. PubMed ID: 10547583
[TBL] [Abstract][Full Text] [Related]
8. [Utility of morphometry and nucleolar organizer regions count in the differentiation of reactive and malignant mesothelial cells in pleural effusions].
Colecchia M; Agnelli T; Caronni E; Leopardi O
Pathologica; 1991; 83(1083):89-97. PubMed ID: 1866205
[TBL] [Abstract][Full Text] [Related]
9. The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions.
Hasteh F; Lin GY; Weidner N; Michael CW
Cancer Cytopathol; 2010 Apr; 118(2):90-6. PubMed ID: 20209622
[TBL] [Abstract][Full Text] [Related]
10. The differential diagnosis of epithelial-type mesothelioma from adenocarcinoma and reactive mesothelial proliferation.
Soosay GN; Griffiths M; Papadaki L; Happerfield L; Bobrow L
J Pathol; 1991 Apr; 163(4):299-305. PubMed ID: 2033489
[TBL] [Abstract][Full Text] [Related]
11. Manual and automated AgNOR count in differentiating reactive mesothelial from metastatic malignant cells in serous effusions.
Mohanty SK; Dey P; Rana P
Anal Quant Cytol Histol; 2003 Oct; 25(5):273-6. PubMed ID: 14603724
[TBL] [Abstract][Full Text] [Related]
12. Keratin and epithelial membrane antigen immunoreactivity in nonneoplastic fibrous pleural lesions: implications for the diagnosis of desmoplastic mesothelioma.
Epstein JI; Budin RE
Hum Pathol; 1986 May; 17(5):514-9. PubMed ID: 2422109
[TBL] [Abstract][Full Text] [Related]
13. Reactive mesothelial hyperplasia vs mesothelioma, including mesothelioma in situ: a brief review.
Henderson DW; Shilkin KB; Whitaker D
Am J Clin Pathol; 1998 Sep; 110(3):397-404. PubMed ID: 9728617
[TBL] [Abstract][Full Text] [Related]
14. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
Friedman MT; Gentile P; Tarectecan A; Fuchs A
Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
[TBL] [Abstract][Full Text] [Related]
15. AgNOR (nucleolar organizer regions) staining in malignant melanoma.
Nagatani T; Iemoto G; Miyakawa K; Ichiyama S; Takahashi Y; Uchiyama M; Nakajima H
J Dermatol; 1991 Dec; 18(12):731-5. PubMed ID: 1806604
[TBL] [Abstract][Full Text] [Related]
16. The value of epithelial membrane antigen expression in separating benign mesothelial proliferation from malignant mesothelioma: a comparative study.
Saad RS; Cho P; Liu YL; Silverman JF
Diagn Cytopathol; 2005 Mar; 32(3):156-9. PubMed ID: 15690334
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic relevance of silver stained nucleolar organizer region (AgNORs) in benign and malignant breast lesions.
Agarwal PK; Mehrotra A; Chandra T
Indian J Exp Biol; 1995 Oct; 33(10):715-20. PubMed ID: 8575800
[TBL] [Abstract][Full Text] [Related]
18. [Study on diagnostic value of analyzing argyrophilic nucleolar organizer regions in benign and malignant pleural effusions].
Jiang S; Zeng Z; Liao Z
Zhonghua Jie He He Hu Xi Za Zhi; 1998 Jan; 21(1):34-6. PubMed ID: 11263298
[TBL] [Abstract][Full Text] [Related]
19. Distinguishing benign from malignant mesothelial cells in effusions by Glut-1, EMA, and Desmin expression: an evidence-based approach.
Kuperman M; Florence RR; Pantanowitz L; Visintainer PF; Cibas ES; Otis CN
Diagn Cytopathol; 2013 Feb; 41(2):131-40. PubMed ID: 23002041
[TBL] [Abstract][Full Text] [Related]
20. Argyrophilic staining of nucleolar organizer region count and morphometry in benign and malignant melanocytic lesions.
Li LX; Crotty KA; Palmer AA; Kril JJ; Scolyer RA; Thompson JF; McCarthy SW
Am J Dermatopathol; 2003 Jun; 25(3):190-7. PubMed ID: 12775980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
